A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC
Condition(s):Triple Negative Breast CancerLast Updated:August 8, 2019Suspended
Hide Studies Not Open or Pending
Condition(s):Triple Negative Breast CancerLast Updated:August 8, 2019Suspended
Condition(s):Squamous Non Small Cell Lung CancerLast Updated:August 8, 2023Active, not recruiting
Condition(s):Cancer of the LiverLast Updated:May 10, 2017Terminated
Condition(s):Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic ChemotherapyLast Updated:September 5, 2021Active, not recruiting
Condition(s):GliomaLast Updated:March 26, 2024Recruiting
Condition(s):NeoplasmLast Updated:July 4, 2011Completed
Condition(s):Ovarian Cancer With Malignant AscitesLast Updated:April 24, 2013Unknown status
Condition(s):Pancreatic Cancer Metastatic; Pancreatic Cancer Stage IV; Stage IV Pancreatic CancerLast Updated:May 25, 2022Completed
Condition(s):Metastatic Pancreatic CancerLast Updated:August 22, 2022Completed
Condition(s):Neoplasms; Carcinoma, Squamous; Antineoplastic AgentsLast Updated:July 27, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.